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Abstract
Background: Fibromyalgia is a prevalent and disabling disorder characterized by widespread pain
and other symptoms such as insomnia, fatigue or depression. Catastrophization is considered a key
clinical symptom in fibromyalgia; however, there are no studies on the pharmacological or
psychological treatment of catastrophizing. The general aim of this study is to assess the
effectiveness of cognitive-behaviour therapy and recommended pharmacological treatment for
fibromyalgia (pregabalin, with duloxetine added where there is a comorbid depression), compared
with usual treatment at primary care level.
Method/design: Design: A multi-centre, randomized controlled trial involving three groups: the
control group, consisting of usual treatment at primary care level, and two intervention groups,
one consisting of cognitive-behaviour therapy, and the other consisting of the recommended
pharmacological treatment for fibromyalgia.
Setting: 29 primary care health centres in the city of Zaragoza, Spain.
Sample: 180 patients, aged 18–65 years, able to understand and read Spanish, who fulfil criteria for
primary fibromyalgia, with no previous psychological treatment, and no pharmacological treatment
or their acceptance to discontinue it two weeks before the onset of the study.
Intervention: Psychological treatment is based on the manualized protocol developed by Prof. Escobar
et al, from the University of New Jersey, for the treatment of somatoform disorders, which has been
adapted by our group for the treatment of fibromyalgia. It includes 10 weekly sessions of cognitive-
behaviour therapy. Pharmacological therapy consists of the recommended pharmacological
treatment for fibromyalgia: pregabalin (300–600 mg/day), with duloxetine (60–120 mg/day) added
where there is a comorbid depression).
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Measurements: The following socio-demographic data will be collected: sex, age, marital status,
education, occupation and social class. The diagnosis of psychiatric disorders will be made with the
Structured Polyvalent Psychiatric Interview. Other instruments to be administered are the Pain
Catastrophizing Scale, the Hamilton tests for Anxiety and for Depression, the Fibromyalgia Impact
Questionnaire (FIQ), the EuroQuol-5 domains (EQ-5D), and the use of health and social services
(CSRI). Assessments will be carried out at baseline, 1, 3, and 6 months.
Main variable: Pain catastrophizing.
Analysis: The analysis will be per intent to treat. We will use the general linear models of the SPSS
version 15 statistical package, to analyse the effect of the treatment on the result variable (pain
catastrophizing).
Discussion: It is necessary to assess the effectiveness of pharmacological and psychological
treatments for pain catastrophizing in fibromyalgia. This randomized clinical trial will determine
whether both treatments are effective for this important prognostic variable in patients with
fibromyalgia.
Trial registration: Current Controlled Trials ISRCTN10804772
Background
The roleof catastrophizing inmediating responses topainhas
received considerable attention in recent years [1-3] and a
consistent relation between catastrophizing and distress
reactions to painful stimulation has been demonstrated [3].
Although the defining criteria for catastrophizing have never
been explicitly stated, there is general consensus that this
construct involves anexaggeratednegativeorientation toward
noxious stimuli. The aetiology of pain catastrophizing is not
clear. It has been demonstrated that interpersonal mechan-
isms may not play a significant role in its development [4],
while insecure attachment would be positively associated
with it [5]. Some of the consequences that have been
associated with pain catastrophizing are more intense pain
[6], heightened pain behaviour [7-9], greater analgesic
consumption [10,11], reduced involvement in daily activities
[3], occupationaldisability [12-14]andsuicidal ideation [15].
A positive association has been documented between
depression and catastrophism [16], but this construct is
different from the negative thoughts found in depression.
Depressive thoughts are only present associated with
depressive mood; however, catastrophism is considered a
continuous psychological variable, normally distributed
even in healthy individuals without pain or depression [17].
The kinds of cognitions are also different: depressive
thoughts are related to depression and similar concepts
such as inferiority, guilt or suicide. Catastrophism cogni-
tions are exclusively focused on pain: a negative vision on it
(magnification), continuously thinking on it (rumination)
and impossibility to control it (helplessness).
A scale to measure catastrophizing, the Pain Catastro-
phizing Scale (PCS), has been developed and validated
[6]. The PCS is a 13-item self-report questionnaire
derived partially from the Coping Strategies Question-
naire [16] and other descriptions of catastrophization
[1,18,19]. It comprises three dimensions: (a) rumina-
tion, (b) magnification and (c) helplessness. Its validity
and reliability have been previously reported [6]. Our
group has validated the Spanish version of this ques-
tionnaire [20].
Fibromyalgia is a prevalent and disabling disorder character-
ized by a history of widespread pain for at least threemonths
andpatient reportingof tenderness in at least 11of18defined
tenderpointswhendigitallypalpatedwithabout4kgperunit
area of force [21]. Catastrophization is considered a key
clinical symptom in fibromyalgia and, in fact, the most used
classification of fibromyalgia clinical subtypes includes
catastrophization as one of the discriminating variables
[22]. However, despite its importance, there is only one
study on the psychological treatment of catastrophizing in
which the only outcome assessed is the general satisfaction of
thepatientandhis/herknowledgeaboutcatastrophizing[23].
Our group has long experience in the treatment of somato-
form disorders/fibromyalgia [24,25] and has developed a
pioneer psychological treatment of catastrophizing that has
proven effective in pilot studies [26].
Methods/Design
Objectives
The general aim of the present study is to assess the
effectiveness of cognitive-behaviour therapy and recom-
mended pharmacological treatment for fibromyalgia (prega-
balin, with duloxetine added where there is comorbid
depression), compared with usual treatment at primary care
level. The specific objective is todetermine the factors (mainly
depression and pain) that predict the response of catastro-
phizing to these treatments.
Trials 2009, 10:24 http://www.trialsjournal.com/content/10/1/24
Page 2 of 7
(page number not for citation purposes)
Design
This is a multi-centre, controlled trial with a random
allocation of patients into three alternative branches (see
Figure 1):
1. Cognitive-behaviour treatment
2. Recommended pharmacological treatment (prega-
balin), associated to antidepressant (duloxetine) if
there is a comorbid depression.
3. Treatment as usual at primary care level.
The evaluation of the treatment outcomes will be
performed at patient level and they will be assessed
individually.
Setting and study sample
Patients will be recruited from any of the 29 primary
health care centres in the city of Zaragoza, Spain. Patients
will be recruited by doctors working in these primary
care centres until the required sample is completed,
without a quota of patients assigned for each centre.
Patients considered for inclusion are those aged 18–65
years, able to understand and read Spanish, who fulfil
criteria for primary fibromyalgia according to the
American College of Rheumatology [21], no previous
psychological treatment, no pharmacological treatment
or their acceptance to discontinue it two weeks before
the onset of the study, and sign informed consent. Those
excluded will be patients with severe Axis I psychiatric
disorders (dementia, schizophrenia, paranoid disorder,
abuse of alcohol and/or drug disorders), severe Axis II
disorders from the clinician point of view that prevent
from following the treatment protocol, pregnancy or
lactation, and refusal to participate.
Randomization, allocation and masking of study groups
Each patient will be allocated to either one of the three
groups using a computer-generated random number
sequence. The allocation will be carried out by an
independent person, belonging to REDIAPP (Research
Network on Preventative Activities and Health Promotion),
Monitoring: baseline, 1, 3 
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Figure 1
Flowchart: randomization, sampling and monitoring of patients.
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who is not involved in the study. The method used to
implement the randomallocation sequencewill be a central
telephone. The sequence will be concealed until interven-
tions are assigned. Patients agree to participate before the
random allocation and without knowing which treatment
they will be allocated to. Pharmacological treatment will be
administered by one psychiatrist (JGC). Study personnel
conducting psychological assessments (YLH) will be
masked to participants' treatment conditions.
Intervention
Psychological intervention
Manualized protocol developed by Prof. Escobar et al,
from the University of New Jersey, for the treatment of
somatoform disorders, which has been adapted by our
group for the treatment of fibromyalgia [26]. It includes
10 weekly sessions of cognitive-behaviour therapy.
Pharmacological intervention
In this group of patients, pregabalin (300–600mg/day), the
recommended treatment for fibromyalgia will be adminis-
tered, associated with duloxetine (60–120 mg/day) for the
patients in whom a major depression disorder is diagnosed
[27]. Pharmacological treatment will be administered and
followed-up by a psychiatrist (JGC).
Treatment as usual at primary care level
This group will continue usual care at primary care level.
Measurements
The study personnel carrying out the measurements (RM,
MA) will be unaware of which treatment the patients are
being administered ("blind"). The follow-up assessments
will take place at baseline, 1, 3 and 6 months.
Variables and instruments of measurement (See Table 1)
Main outcome variables
In accordance with the aims of the study, the major
outcome is pain catastrophizing in patients with fibro-
myalgia. This construct will be assessed with the Spanish
version [20] of the Pain Catastrophizing Scale [6].
Secondary variables
The following socio-demographic data will be collected:
sex, age, marital status (single, married/relationship,
separated/divorced, and widowed), education (no stu-
dies, primary, lower secondary, upper secondary, uni-
versity), occupation and social class (I, II, IIIN, IIIM, IV
and V of the British Registrar General's Scale) [29].
The diagnosis of psychiatric disorders will be made with the
Structured Polyvalent Psychiatric Interview [30], a psychiatric
interview developed by our group and extensively used for
the study of somatoform disorders, the group in which
fibromyalgia is included in psychiatric classifications.
Hamilton Anxiety Rating Scale (HARS) [31]. This is a
clinician-administered rating scale that consists of 14
items. Each item is rated on a 5-point scale (from 0 = no
symptoms to 4 = severe, grossly disabling symptoms.
Total scores for the HAS range from 0 to 56. A score of >=
14 has been suggested to indicate clinically significant
anxiety. It has a Spanish validated version [32]
Hamilton Rating Scale for Depression (HAM-D) [33].
This is probably the most used observer-rated depressive
symptom rating scale. Although the original scale had 21
items, Hamilton suggested scoring only the initial 17
items because the last 4 items either occurred infre-
quently or described only aspects of the illness. Items are
ranked on a scale of 0–4 (items with quantifiable
severity) or 0–2 (items that measure symptoms more
difficult to assess reliably). The greatest severity is
indicated by 2 or 4. The range for the 17-item scale is
0–50. We have used the Spanish validated version [34].
Table 1: Study variables
Instrument Assessment area Time(s) of assessments Applied by
Sampling form assistant Age, sex, inclusion/exclusion criteria Baseline Research
Sociodemographic data form assistant Age, sex, marital status, educational level, Baseline Research
Socio-economic group [29], occupation
SPPI psychiatric interview psychiatrist [30] Psychiatric diagnosis Baseline Research
Pain catastrophizing scale [20] assistant Severity of catastrophizing Baseline and follow-up sessions* Research
Hamilton test for Depression assistant [31,32] Severity of depression Baseline and follow-up sessions* Research
Hamilton test for Anxiety assistant [33,34] Severity of anxiety Baseline and follow-up sessions* Research
Fibromyalgia Impact assistant Questionnaire [35,36] General function Baseline and follow-up sessions* Research
Medical record assistant Pharmacological Follow-up sessions* side-effect events Research
EQ-5D [37] assistant Health related quality of life Baseline and follow-up sessions* Research
CSRI [38] assistant Health and social services use Baseline and follow-up sessions* Research
*Follow-up sessions: 1, 3, and 6 months.
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Fibromyalgia Impact Questionnaire (FIQ) [35]: The FIQ
is a 10-item self-report questionnaire developed to
measure the health status of FM patients. The first item
focuses on the patient's ability to carry out muscular
activities. In the next two items, patients are asked to
circle the number of days in the past week they felt good
and how often they missed work. Finally, the last seven
questions (job ability, pain, fatigue, morning tiredness,
stiffness, anxiety and depression) are measured by visual
analogue scale (VAS). This instrument has a translated
and validated Spanish version [36].
EuroQoL-5D questionnaire (EQ-5D – Spanish version)
[37]: Generic instrument of health-related quality of life.
It has two parts: Part 1 records self-reported problems in
each of five domains: mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. Each domain is
divided into three levels of severity corresponding to no
problems, some problems, and extreme problems. Part 2
records the subject's self-assessed health on a VAS – a 10-
cm vertical line on which the best and worst imaginable
health states score 100 and 0, respectively.
Client Service Receipt Inventory – adapted (CSRI – Spanish
version) [38]: Questionnaire for collecting information
about use of healthcare and social care services, other
economic impacts (such as time off work due to illness) and
socio-demographic information. The variant used in this
study was designed to collect retrospective data on service
utilization during the previous six months.
Statistical methods
Sample size
To calculate the sample size, it is necessary to know the
effectiveness of pharmacological and psychological on
the main outcome variable, pain catastrophizing. Unfor-
tunately, there are no prior published studies on this
subject. Based on our clinical experience, we assume this
rate will be by 20% [26]. We aim to detect a difference of
20% or more between any of the groups (control and
intervention). Accepting an alpha risk of 0.05 and a beta
risk of < 0.20 in a bilateral contrast, we would need 55
patients in each group [28]. Calculating 10% of refusals
as found in previous studies [27], we will need a sample
size of 60, which implies a total sample of 180 patients
with fibromyalgia.
Analysis strategy
The analysis will be per intent to treat. First we will
compare the three groups in order to verify that there are
no significant differences among them (socio-demo-
graphic characteristics, clinical baseline data, etc). We
will use the mean (standard deviation) in the continuous
variables and percentages in the categorical variables. For
comparisons we will use the Kruskal-Wallis for contin-
uous variables and the Chi-squared test for categorical
variables. Non-parametric tests may also be used.
The main variable of the result is pain catastrophizing.
Process variables include socio-demographic characteristics,
severity of the depression (Hamilton test for Depression
(HAM -D), and anxiety (Hamilton test for Anxiety), and
general function (Fibromyalgia Impact Questionnaire).
The general linear models of the SPSS 15 statistical
package will be used to analyse the effect of the
treatment on the categorical result variables (pain
catastrophizing). We will use the analyses of linear
mixed models to study the effect of the continuous
process variables (depression, anxiety, and pain).
Cost-utility analyses
Societal cost perspective will be used for the calculation of
costs. Direct costs will be calculated by adding the costs
derived from any medication and use of health-related
services (general practitioner sessions, specialized medical
sessions, emergency room sessions, and hospital in-patient
stay). The cost of medications will be calculated by
determining the price per milligram during the study,
according to the International Vademecum (Red Book)
2008–2010, including value-added tax. Total costs of
pharmacological treatment will be calculated bymultiplying
the price per milligram by the daily dose in milligrams and
the number of days such treatment is received. Costs derived
from the use of health-related services will be calculated
considering the Oblikue unit costs database [39]. Indirect
costs will be calculated considering the days of sick leave
taken and multiplying them by the minimum daily wage in
Spain for 2007–2009. Finally, total costs will be calculated
by adding direct and indirect costs.
In Spain, the National Health Service (SNS) is financed by
general taxes levied by the state. Medical visits and hospital
admissions are fully covered by the SNS. Medications
prescribed are fully covered for retired persons, with co-
payment for those still in theworkforce. Sick leave requires a
physician's authorization, and patients unable to work
continue to receive most of their salary.
When performing cost-utility analyses, two or more
therapeutic options are compared in order to determine
which one is the best for maximizing the benefits in light
of the available resources [40]. This is achieved by
calculating the relationship between the costs of a given
intervention (e.g. A) and its consequences, expressed in
QALYs, compared with another (e.g. B). This relative
value is called incremental cost-utility ratio (ICUR), and
it expresses the relationship between the costs and effects
of one intervention compared with another.
Trials 2009, 10:24 http://www.trialsjournal.com/content/10/1/24
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As the duration of the study is only 12 months, neither
costs nor outcomes are subject to discounting [40].
Treatment costs during 12 months follow-up will be
modelled by a multivariate gamma regression with a log
link. Gamma modelling has been suggested as a suitable
choice for analysing cost data, taking into account the
skewing of the distribution of the cost data [41,42].
QALYs gained in the first and last sixmonths after the start
of the programme will be approximated by measuring the
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The incremental treatment effect on change in EQ-5D
utility score for the first 6 months is d0–6 and the
incremental treatment effect on change in EQ-5D utility
score for the last 6 months is d6-12. These incremental
treatment effects will be estimated using multivariate
ordinary least squares regressions, adjusting for baseline
differences among treatment groups. The covariates
included in the models will be: age, sex, years of
education, employment and marital status, baseline
FIQ and EQ-5D utility scores, and type of medication
prescribed. To address uncertainty in the ICUR sampling
distribution, non-parametric bootstrapping with five
thousand replications will be carried out for each
treatment comparison [43].
Ethical aspects
Informed consent will be obtained from the participants
before they are aware of which group they are to be
included in. Before they give their consent, the patients
will be provided with a general overview of the aims and
characteristics of the study and the psychological and
pharmacological intervention. They will also be
informed that they will be participating voluntarily,
and that they can choose to withdraw at any time with
the guarantee that they will continue to receive the
treatment considered most appropriate by their doctor.
The study follows Helsinki Convention norms and
posterior modifications and the Declaration of Madrid
of the World Psychiatric Association. The Study Protocol
was approved by the Ethical Review Board of the
regional health authority (ref: PI07/22).
Forecast execution dates
Initial recruitment of patients: April 2009
Finalization of patient recruitment: September 2009
Finalization of patient monitoring period: April 2010
Publication of results: September 2010
Discussion
The effectiveness of pharmacological and psychological
treatments for fibromyalgia has been demonstrated, despite
the size effect being rather limited [44]. Catastrophizing is
considered one of themost importantmodulating variables
in the experience of pain. However, the effectiveness of
treatments for fibromyalgia in catastrophizing has not been
evaluated except in pilot studies [26].
The strength of the study is that, to our knowledge, this is
the first multi-centre, randomized, controlled trial of
psychological and pharmacological treatments for pain
catastrophizing in patients with fibromyalgia compared
with usual treatment.
A number of potential limitations may be difficulties in
recruitment, owing to requisite of discontinue pharma-
cological treatment and changes in employment status
because many patients are either on sick leave or
applying for disability pensions, making it difficult to
interpret the results. The very concept of catastrophizing
has also been criticized, with some authors suggesting
the need of new tools to assess it [45].
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